| Code | CSB-RA980158MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to LYN-00101, targeting vascular endothelial growth factor (VEGF), a critical signaling protein in angiogenesis and vascular development. VEGF plays a central role in promoting endothelial cell proliferation, migration, and survival by binding to specific tyrosine kinase receptors on vascular endothelial cells. Dysregulated VEGF expression is implicated in numerous pathological conditions, including cancer progression and metastasis, age-related macular degeneration, diabetic retinopathy, and various inflammatory disorders where abnormal blood vessel formation contributes to disease pathology.
LYN-00101 serves as the reference therapeutic antibody for this biosimilar development, representing a well-characterized anti-VEGF agent used in clinical and research settings. This biosimilar antibody provides researchers with a valuable tool for investigating VEGF-mediated signaling pathways, studying angiogenesis mechanisms, evaluating anti-angiogenic therapeutic strategies, and exploring VEGF's role in tumor microenvironments and vascular biology. The antibody supports diverse experimental approaches in oncology, ophthalmology, and cardiovascular research.
There are currently no reviews for this product.